Sponsors

Lead Sponsor

Annexon, Inc.

This is a phase 1, open-label, dose-escalation, safety study evaluating up to 3 dose levels of ANX007 administered as single IVT injections. Approximately 9 to 15 eligible participants are enrolled into one cohort each. All participants receive ANX007 in an open-label manner. The primary objective is to evaluate the safety and tolerability of a single intravitreal (IVT) injection of ANX007 in participants with primary open-angle glaucoma. Secondary objectives are to evaluate the serum pharmacokinetics (PK) and immunogenicity. An exploratory objective will evaluate the pharmacodynamic (PD) effect of ANX007 on serum C1q activity.

Related studies

RECRUITINGNA

A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

NCT06267274 · Open-angle Glaucoma, Ocular Hypertension

Enrolling By InvitationNA

MINIject Implantation Combined With Cataract Surgery in Patients With POAG and Cataract

NCT05432245 · Primary Open-angle Glaucoma, Cataract

View all related studies →

Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma

What this study is about

Save this trial guide to your notes

Sponsors

Related studies

Aqueous Humor and Ocular Tissue Analysis in Glaucoma and Cataract

Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use

Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation

A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

MINIject Implantation Combined With Cataract Surgery in Patients With POAG and Cataract

Trial snapshot

Condition

Locations shown

For caregivers